LIVEPERSON INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIVEPERSON INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $249.84M | Feb 25, 2019 |
| FY2018 | Dec 31, 2017 | $218.88M | Feb 25, 2019 |
| FY2018 | Dec 31, 2016 | $222.78M | Feb 25, 2019 |
| FY2017 | Dec 31, 2015 | $239.01M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $209.93M | Mar 10, 2017 |
| FY2015 | Dec 31, 2013 | $177.81M | Mar 15, 2016 |
| FY2012 | Dec 31, 2012 | $42.48M | Mar 1, 2013 |
| FY2012 | Sep 30, 2012 | $39.67M | Mar 1, 2013 |
| FY2012 | Jun 30, 2012 | $38.51M | Mar 1, 2013 |
| FY2012 | Mar 31, 2012 | $36.76M | Mar 1, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $243.74M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $312.47M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $401.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $514.80M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $469.62M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $366.62M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $291.61M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $249.84M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $218.88M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($67.23M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($134.27M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($100.44M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($225.75M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | ($124.97M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($107.59M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($96.07M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($25.03M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($18.19M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($25.87M) | Feb 25, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($78.70M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($183.20M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($111.38M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($221.88M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | ($93.27M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($89.45M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($87.03M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($23.70M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($17.83M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($19.41M) | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.71M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $79.78M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $103.86M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $193.69M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $158.39M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $108.41M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $82.15M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $55.71M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $40.03M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $40.20M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.44M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($15.13M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($19.77M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($62.10M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.25M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $33.61M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($59.16M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $4.78M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $10.29M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $24.56M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.09M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $25.14M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $28.66M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $48.49M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $45.70M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $41.64M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $47.58M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $21.94M | Mar 8, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $454.67M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $607.78M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $835.51M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.09B | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $1.19B | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.01B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $512.71M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $290.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $232.80M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $219.64M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $499.16M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $675.09M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $787.38M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.02B | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $837.22M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $762.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $364.18M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $119.37M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $92.74M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $81.16M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.50M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($67.32M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $48.14M | Mar 16, 2026 |
| FY2025 | Dec 31, 2022 | $68.09M | Mar 16, 2026 |
| FY2024 | Dec 31, 2021 | $349.44M | Mar 14, 2025 |
| FY2023 | Dec 31, 2020 | $243.93M | Mar 4, 2024 |
| FY2022 | Dec 31, 2019 | $148.54M | Mar 16, 2023 |
| FY2021 | Dec 31, 2018 | $170.73M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $140.06M | Mar 8, 2021 |
| FY2019 | Dec 31, 2016 | $138.48M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.90M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $222.55M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $285.63M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $296.21M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $291.22M | Mar 4, 2024 |
| FY2021 | Dec 31, 2020 | $95.19M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $94.99M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $95.03M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $80.53M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $80.25M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.06B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($991.26M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($856.99M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($692.36M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($516.86M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($391.89M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($283.56M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($187.49M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($163.14M) | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | ($144.94M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.00M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $183.24M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $210.78M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $391.78M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $521.85M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $654.15M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $176.52M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $66.45M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $56.12M | Feb 25, 2019 |
| FY2018 | Dec 31, 2016 | $50.89M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $511.57M | Mar 4, 2024 |
| FY2023 | Dec 31, 2022 | $737.42M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $574.24M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $538.43M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (22) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (19) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 25, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (12) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (22) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (19) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 25, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.04M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 6.08M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 87.84M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 75.58M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 72.23M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 67.55M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 63.83M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 60.99M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 59.66M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | 58.28M | Mar 15, 2018 |